{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(6)"],"submitter":["Xi J"],"pubmed_abstract":["<h4>Background</h4>This study aimed to evaluate the long-term survival outcomes of patients undergoing neoadjuvant chemoradiotherapy or adjuvant chemoradiotherapy for T1-4N0-1M0 disease.<h4>Methods</h4>Patients with pT1-4N0-1M0 between 2010 and 2015 who received pre- or postoperative (R0 resection) chemoradiotherapy were identified. The exclusion criteria included N2 or M1 disease, immunotherapy, and targeted therapy. The staging was recalculated according to the new 8th edition TNM classification. Survival and predictors were assessed using Kaplan-Meier and multivariate Cox proportional-hazards model. Propensity-score matching with a ratio of 2:1 was performed to reduce bias in various clinicopathological factors.<h4>Results</h4>Of the 1,769 patients who met the inclusion criteria, 407 an"],"journal":["Journal of thoracic disease"],"pagination":["3043-3056"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7330800"],"repository":["biostudies-literature"],"pubmed_title":["Long-term outcomes following neoadjuvant or adjuvant chemoradiotherapy for stage I-IIIA non-small cell lung cancer: a propensity-matched analysis."],"pmcid":["PMC7330800"],"pubmed_authors":["Sui Q","Xi J","Hu Z","Chen Z","Zhan C","Liang J","Guo W","Bian Y","Du Y","Li M"],"additional_accession":[]},"is_claimable":false,"name":"Long-term outcomes following neoadjuvant or adjuvant chemoradiotherapy for stage I-IIIA non-small cell lung cancer: a propensity-matched analysis.","description":"<h4>Background</h4>This study aimed to evaluate the long-term survival outcomes of patients undergoing neoadjuvant chemoradiotherapy or adjuvant chemoradiotherapy for T1-4N0-1M0 disease.<h4>Methods</h4>Patients with pT1-4N0-1M0 between 2010 and 2015 who received pre- or postoperative (R0 resection) chemoradiotherapy were identified. The exclusion criteria included N2 or M1 disease, immunotherapy, and targeted therapy. The staging was recalculated according to the new 8th edition TNM classification. Survival and predictors were assessed using Kaplan-Meier and multivariate Cox proportional-hazards model. Propensity-score matching with a ratio of 2:1 was performed to reduce bias in various clinicopathological factors.<h4>Results</h4>Of the 1,769 patients who met the inclusion criteria, 407 an","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jun","modification":"2025-04-22T02:08:40.807Z","creation":"2025-04-05T20:13:19.03Z"},"accession":"S-EPMC7330800","cross_references":{"pubmed":["32642227"],"doi":["10.21037/jtd-20-898"]}}